Form 8-K AbbVie Inc. For: Jul 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Deere shares climb as fiscal Q3 earnings and revenue top estimates
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Abbvie (ABBV) PT Raised to $200 at Goldman Sachs
July 26, 2024 5:53 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $200.00 (from $190.00) while maintaining a Buy rating.
The analyst comments "Even amidst expectations that Immunology would once again deliver, we see basis for the factors underpinning growth for both Skyrizi and Rinvoq to continue propelling upside - including NBRx dynamics that... More
William Blair Reiterates Outperform Rating on Abbvie (ABBV)
July 26, 2024 5:37 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Abbvie (NYSE: ABBV).
The analyst comments "Stock thoughts: We believe AbbVie has a strong and durable growth profile over the coming years thanks to its strong growth platform, recently augmented by the... More
Abbvie (ABBV) PT Raised to $210 at Truist Securities
July 25, 2024 4:12 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "ABBV reported strong 2Q24 results with top and bottom line beats, led by Skyrizi/RInvoq. Given the share... More
Abbvie (ABBV) PT Raised to $210 at JPMorgan
July 25, 2024 3:56 PM EDTJPMorgan analyst Chris Schott raised the price target on Abbvie (NYSE: ABBV) to $210.00 (from $190.00) while maintaining a Overweight rating.
The analyst comments "Exiting 2Q results, we our updating our model and wanted to share our key changes. Overall, we are increasing our estimates to... More
